An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination With Gemcitabine and Cisplatin in the First-Line Treatment of Patients With Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Necitumumab (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly
- 16 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Mar 2018.
- 07 Jun 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
- 07 Jun 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jun 2017.